Experiments in mouse models targeting CEACAM1 expression globally or in the liver shed more light on how hepatic CEACAM1 exhibits unique regulatory properties connecting insulin clearance and lipid metabolism to the pathogenesis of NAFLD/NASH. Here, INS is linked to metabolic dysfunction-associated steatotic liver disease.